Teva Stock Falls On Unusually High Volume (TEVA)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Teva Pharmaceutical Industries (NYSE: TEVA) is trading at unusually high volume Wednesday with 16.3 million shares changing hands. It is currently at 4.8 times its average daily volume and trading down $2.07 (-5%) at $39.60 as of 2:41 p.m. ET.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Teva has a market cap of $36.91 billion and is part of the health care sector and drugs industry. Shares are up 5.4% year to date as of the close of trading on Tuesday.

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. The company has a P/E ratio of 11.5, below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Teva as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. You can view the full Teva Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Five-Day Winning Streak in Stocks Expected to Continue

Five-Day Winning Streak in Stocks Expected to Continue

Dow Jumps Over 300 Points, Posting Its Fifth Straight Day of Gains

Dow Jumps Over 300 Points, Posting Its Fifth Straight Day of Gains

Stock Markets Around the World Are Soaring Again

Stock Markets Around the World Are Soaring Again

Jim Cramer: The SEC Should Admit It Goofed With These Crazy Instruments

Jim Cramer: The SEC Should Admit It Goofed With These Crazy Instruments